Metagenomi Therapeutics (MGX) Free Cash Flow (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Free Cash Flow of -$21.3 million for Q1 2026, up 7.92% year-over-year from -$19.7 million in Q1 2025, and up 9.87% quarter-over-quarter from -$23.6 million in Q4 2025.
Metagenomi Therapeutics (MGX) Free Cash Flow (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Free Cash Flow for 4 consecutive years, with -$21.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 7.92% year-over-year to -$21.3 million; the TTM figure through Mar 2026 stood at -$87.6 million (up 16.58% YoY), while the FY2025 annual figure was -$89.5 million, up 20.25% from the prior year.
- Free Cash Flow grew to -$21.3 million in Q1 2026 per MGX's latest filing, from -$23.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$13.2 million in Q4 2023 and bottomed at -$30.5 million in Q2 2023.
- Historically, Free Cash Flow has averaged -$24.2 million across 4 years, with a median of -$23.6 million in 2025.
- Annual changes were most pronounced in 2024 — Free Cash Flow sank 102.31% — and 2025, when it gained 24.72%.
- Metagenomi Therapeutics' Free Cash Flow stood at -$13.2 million in 2023, then sank by 102.31% to -$26.6 million in 2024, then advanced by 11.2% to -$23.6 million in 2025, then increased by 9.87% to -$21.3 million in 2026.
- Business Quant data shows MGX's Free Cash Flow at -$21.3 million in Q1 2026, -$23.6 million in Q4 2025, and -$21.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | -19.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.54 Mn |
| Jun 30, 2026 | -19.54 Mn |
| Mar 31, 2026 | -21.30 Mn |
| Mar 31, 2026 | -21.30 Mn |
| Dec 31, 2025 | -23.63 Mn |
| Dec 31, 2025 | -23.63 Mn |
| Sep 30, 2025 | -21.33 Mn |
| Sep 30, 2025 | -21.33 Mn |
| Jun 30, 2025 | -21.38 Mn |
| Jun 30, 2025 | -21.38 Mn |
| Mar 31, 2025 | -23.13 Mn |
| Mar 31, 2025 | -23.13 Mn |
| Dec 31, 2024 | -26.61 Mn |
| Dec 31, 2024 | -26.61 Mn |
| Sep 30, 2024 | -28.33 Mn |
| Sep 30, 2024 | -28.33 Mn |
| Jun 30, 2024 | -26.98 Mn |
| Jun 30, 2024 | -26.98 Mn |
| Mar 31, 2024 | -30.27 Mn |
| Mar 31, 2024 | -30.27 Mn |